EN
Home/United Arab Emirates/Answers/Ozempic for weight loss
AEUnited Arab Emirates Medicines

Is Ozempic for weight loss in the UAE?

GLP Guidebook teamUpdated 18 Oct 202616 sourcesWritten from published sources
What we checked16 sources, each one opened and linked to the sentence it supportsLast checked 18 Oct 2026 · Next review due 18 Oct 2027 · How we write
The short answer

No. In the UAE, Ozempic (semaglutide) is approved for type 2 diabetes, not weight loss. The same medicine is approved for weight as Wegovy, at up to 2.4 mg a week, against Ozempic's top dose of 2 mg. Using Ozempic for weight would be off-label, and Dubai's basic insurance plan excludes weight-loss medicines.

Before you go further
  • GLP‑1 medicines are prescription-only in the UAE and should only be used under a doctor's supervision, Abu Dhabi's Department of Health says.1
  • We don't name, link or rank sellers, and nothing here is for sale. Official prices are on the prices page.

Why do people call Ozempic a weight-loss drug?

Semaglutide is the medicine. Ozempic and Wegovy are two brands of it, and in the UAE Ozempic is listed for type 2 diabetes, Wegovy for obesity.2,3

Three things made the Ozempic name stick:

  • It came first. Europe approved Ozempic in February 2018 and Wegovy in January 2022.4,5 We found no published UAE approval dates for either.
  • The weight loss showed up in diabetes trials. In SUSTAIN 1, 388 adults with type 2 diabetes lost 3.7 kg (8 lb) on Ozempic 0.5 mg and 4.5 kg (10 lb) on 1 mg over 30 weeks, against 1.0 kg on a dummy injection.6
  • Demand ran ahead of the weight brand. Novo Nordisk, the maker, told The National in 2024 that it brought Wegovy to the UAE "specifically for obesity, and Ozempic is for diabetes".7

How the two brands compare is in Guide 2, and all the UAE brands are in its family tree.

What does "off-label" mean?

Off-label means using a medicine for a purpose its approval doesn't cover, judged against the approval in the country where it is used.8

That wording is the European Medicines Agency's; we found no UAE regulator's own definition, and no UAE rule written about doctors prescribing off-label. A UAE-licensed doctor's prescription is still needed,1 and Daman's GLP‑1 guideline says treatment decisions remain the doctor's responsibility.2

What does that mean for you in the UAE?

Ozempic for weight is unlikely to be insured, stops at a lower dose than Wegovy, and has run short before.

  • Insurance. Dubai's basic Essential Benefits Plan excludes "pharmacological weight reduction regimens".9 Daman lists Ozempic for type 2 diabetes only, and pays for obesity medicines only within Abu Dhabi's Thiqa Obesity Program.2 More in Is Ozempic covered by insurance in the UAE?
  • The dose. Ozempic's label stops at 2 mg a week.6 Wegovy pens in the UAE go up to 2.4 mg.10 Europe also approves Wegovy 7.2 mg, but the UAE had not as of March 2026.11,12 See Is Wegovy 7.2 mg available in the UAE?
  • Supply. In April 2023 pharmacies in Dubai and Sharjah told The National that "genuine diabetes patients can't get the medication".13 Novo Nordisk said it had "big problems" with supply in 2023 and late 2022.7 We found no UAE rule telling doctors to keep Ozempic for diabetes.
  • Safety. It is the same medicine, so the side effects below apply to both brands.6

Mounjaro is different. Mounjaro (tirzepatide) is listed in the UAE for type 2 diabetes and for weight, so this question doesn't apply to it.2,3 See Is Zepbound available in the UAE? and how the brands compare.

RisksThe risks, in brief
  • Stomach effects are very common. The EU Ozempic leaflet lists feeling sick and diarrhoea in more than 1 in 10 people.6
  • Inflamed pancreas (acute pancreatitis) is uncommon, up to 1 in 100, on the EU Ozempic leaflet.6
  • Low blood sugar is very common when Ozempic is taken with insulin or a sulfonylurea, a type of diabetes tablet.6
  • Pregnancy. The EU label says stop semaglutide at least 2 months before a planned pregnancy.6
Full detail in Guide 5: Side effects and risks →
Get help now: call 998 for an ambulance, or 999, if you have severe pain in the stomach and back that does not go away, or swelling of the face, lips, tongue or throat with trouble breathing.6,14

What does a doctor weigh?

A doctor weighs your health against the UAE rules, and whether a medicine approved for weight would suit you better.

  • Your BMI. Abu Dhabi's standard allows GLP‑1s from a BMI of 30 with a weight-related condition, or over 40.15 Dubai's guideline allows a BMI over 30, or 27 to 29.9 with a condition, after lifestyle changes alone haven't worked.16
  • Whether it is working. Abu Dhabi's standard continues a GLP‑1 beyond 6 months only if you have lost at least 5% of your starting weight.15
  • Your other medicines and plans, such as diabetes treatment that can cause low blood sugar, or a pregnancy.6

Read the full picture

Related questions

Is Ozempic covered by insurance in the UAE? Can I buy Ozempic without a prescription in the UAE? Is Wegovy 7.2 mg available in the UAE? Is Zepbound available in the UAE? What BMI do I need for weight-loss injections in the UAE?
Did this answer your question?

Sources

  1. Department of Health – Abu Dhabi. Circular 48/2026, 16 Mar 2026: GLP-1 receptor agonists "are prescription-only medicines and should only be used under medical supervision". Summarised, not reproduced. Checked 18 Oct 2026. doh.gov.ae (PDF)
  2. Daman (National Health Insurance Company). Glucagon-like Peptide-1 (GLP-1) Receptor Agonist adjudication guideline, V5, effective 15 Jan 2023, revised 19 Apr 2026. Table 1: "Semaglutide (Ozempic) – Type 2 Diabetes Mellitus"; Wegovy "Obesity management and … (MASH)"; Mounjaro "Type 2 Diabetes Mellitus, Obesity Management". Section 3.3: obesity medicines "not covered for members who are not enrolled in the Thiqa Obesity Program". Disclaimer: treatment "remains at all times the sole responsibility of the treating Healthcare Provider". Checked 18 Oct 2026. damaninsurance.ae (PDF)
  3. Dubai Health Authority. Ejada KPIs and Recommendations: Obesity and Metabolic Syndrome, issued 3 Sep 2024: tirzepatide (Mounjaro) and semaglutide (Wegovy) "registered for obesity pharmacotherapy in UAE". Checked 18 Oct 2026. isahd.ae (PDF)
  4. European Medicines Agency. Ozempic (semaglutide): EPAR overview, marketing authorisation 8 Feb 2018, for type 2 diabetes. Checked 18 Oct 2026. ema.europa.eu
  5. European Medicines Agency. Wegovy (semaglutide): EPAR overview, marketing authorisation 6 Jan 2022, for weight management. Checked 18 Oct 2026. ema.europa.eu
  6. European Medicines Agency. Ozempic (semaglutide) product information: SmPC 4.2 ("Weekly doses higher than 2 mg are not recommended"), 4.6 (stop at least 2 months before a planned pregnancy), 4.8 and 5.1 (SUSTAIN 1, Table 2: weight −3.7 kg on 0.5 mg, −4.5 kg on 1 mg, −1.0 kg on placebo at week 30; 388 patients), and the package leaflet, section 4. EU label; UAE label text not checked. Checked 18 Oct 2026. ema.europa.eu (PDF)
  7. The National. Ozempic maker urges UAE users to switch to Wegovy for weight loss, 22 May 2024 (Novo Nordisk UAE general manager: "Wegovy because this is specifically for obesity, and Ozempic is for diabetes"; "big problems in 2023 and also at the end of 2022"). Checked 18 Oct 2026. thenationalnews.com
  8. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP), Annex I: definitions (Rev 4), "Off-label use": "The reference terms for off-label use are the terms of marketing authorisation in the country where the product is used." Checked 18 Oct 2026. ema.europa.eu (PDF)
  9. Cigna. Essential Benefits Plan (EBP), Dubai, table of benefits (DHA-regulated basic plan), exclusions 8 and 9: "Surgical and non-surgical treatment for obesity" and "pharmacological weight reduction regimens". Checked 18 Oct 2026. cigna-me.com (PDF)
  10. Department of Health – Abu Dhabi. Shafafiya drug price list (Drugs.xlsx), effective 2 Oct 2026: Ozempic 2 mg/dose pen and Wegovy FlexTouch 0.25 to 2.4 mg/dose pens listed as active; no 7.2 mg pack. Checked from the downloaded list, 18 Oct 2026. shafafiyaportal.doh.gov.ae (XLSX)
  11. European Medicines Agency. Wegovy (semaglutide) product information, SmPC 4.2: maintenance dose 2.4 mg, which "can be increased to 7.2 mg once weekly". EU label. Checked 18 Oct 2026. ema.europa.eu (PDF)
  12. Gulf News. Higher maintenance dose of weight-loss drug Wegovy approved in EU: when will UAE get it? ("discussions with UAE regulators are ongoing, though no timeline has been set"). 2 Mar 2026. Checked 18 Oct 2026. gulfnews.com
  13. The National. Diabetes drugs being used for weight loss leads to shortage in UAE market, 7 Apr 2023 ("Genuine diabetes patients can't get the medication because it's sold quickly"). Checked 18 Oct 2026. thenationalnews.com
  14. Department of Digital Ajman. Handling emergencies ("999 for Police", "998 for Ambulance"). Checked 18 Oct 2026. ajman.ae
  15. Department of Health – Abu Dhabi. Standard for Non-Surgical Management of Obesity, DOH/ST/HPS/Non-Surgical-MO/V1/2025, February 2025, section 3.4.2.2.1 (GLP-1 starting criteria: BMI of at least 30 with one or more weight-related comorbidities, or over 40; continue beyond 6 months only after at least 5% weight loss). Checked 18 Oct 2026. doh.gov.ae (PDF)
  16. Dubai Health Authority. Clinical Guidelines for Virtual Management of Obesity, DHA/HRS/HPSD/CG-53, issue 2, effective 21 Apr 2024, section 11.9.1 (drug therapy for BMI over 30, or 27 to 29.9 with comorbidities, after lifestyle intervention). Checked 18 Oct 2026. dha.gov.ae (PDF)

Last checked 18 Oct 2026 · Next review due 18 Oct 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on 18 Oct 2026. We don't name, link or rank sellers, and nothing here encourages using a medicine outside its approval. It's general information, not medical advice. Talk to a UAE-licensed doctor or pharmacist before starting, stopping or changing any medicine. How we write